Inflammation & Allergy-Drug Targets

(Formerly Current Drug Targets - Inflammation & Allergy)

Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448


The Pathology and Immunology of Atopic Dermatitis

Author(s): Saifur Rahman, Mary Collins, Cara M. M. Williams and Hak-Ling Ma

Affiliation: Inflammation and Autoimmunity Research Unit, Pfizer Inc., 200 Cambridge Park Drive, Cambridge, MA 02140, USA.


Atopic dermatitis (AD) is a pruritic chronic inflammatory disease of the skin that is triggered by an underlying complicated interplay between the genetics of the individual and stimulation by allergens. Patients with AD demonstrate compromised barrier function that leads to activation of keratinocytes and immune cells which favor a strong Th2 bias. As a result of this immunological bias such patients also suffer from secondary pathogenic infections. A wide array of cytokines and chemokines interact to yield symptoms characteristic of AD. In addition, the involvement of different immunological cell types compounds our difficulty in understanding its immunopathogenesis. The use of various mouse models and transgenics has allowed us to intricately examine the functioning of the various molecules identified to play a role in AD. Such mouse models have also aided in the testing and development of various therapeutics for AD. This review is focused on examining the various factors contributing to the pathogenesis and exacerbation of AD as well as current treatments for AD. There is scope for improving the therapy of AD patients and thereby allowing them a better quality of life.

Keywords: Atopic dermatitis, allergic inflammation, skin inflammation, filaggrin, barrier dysfunction, cytokine, chemokine, immune cells, keratinocyte, mouse models, therapeutics

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [486 - 496]
Pages: 11
DOI: 10.2174/187152811798104935